LAX.SH
ADVANCED ENZYME TECH LTD·PHARMACEUTICALS 70.24·Pharmaceuticals & Biotechnology Companies
Price
300
-1%52W Range
Market Cap
₹3,359.28 Cr
Traded: ₹13.92 Cr (0.41%) 0.0x
Free Float: ₹738.71 Cr (1.88% of FF traded)
Volume · 60D trend
4.58 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +10.0% | +8.0% | +11.0% | -- | +12.0% | Accelerating |
| ROE | +13.0% | +10.0% | +10.0% | -- | -- | Stable |
| Return | +1.0% | -5.0% | +0.0% | +6.0% | -- | Accelerating |
| Profit | +7.0% | +1.0% | +12.0% | -- | +15.0% | Accelerating |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 190 | 203 | 172 | 185 | 186 | 167 | 169 | 146 | 155 | 158 | 161 | 158 | 147 | 139 | 142 | 139 |
| Expenses | 139 | 140 | 123 | 124 | 129 | 122 | 114 | 104 | 103 | 102 | 107 | 107 | 103 | 95 | 100 | 99 |
| Operating Profit | 51 | 63 | 49 | 60 | 56 | 46 | 55 | 42 | 51 | 55 | 54 | 51 | 44 | 44 | 42 | 40 |
| OPM % | 27.0% | 31.0% | 29.0% | 33.0% | 30.0% | 27.0% | 33.0% | 29.0% | 33.0% | 35.0% | 33.0% | 32.0% | 30.0% | 32.0% | 29.0% | 29.0% |
| Other Income | 13 | 7 | 20 | 10 | 9 | 9 | 8 | 10 | 7 | -6 | 14 | 6 | 7 | 7 | 9 | 4 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 10 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 9 | 9 |
| Profit Before Tax | 54 | 60 | 58 | 60 | 55 | 43 | 53 | 42 | 49 | 40 | 59 | 48 | 41 | 42 | 40 | 34 |
| Tax % | 28.0% | 24.0% | 26.0% | 25.0% | 26.0% | 38.0% | 27.0% | 21.0% | 28.0% | 25.0% | 28.0% | 27.0% | 29.0% | 24.0% | 31.0% | 23.0% |
| Net Profit | 39 | 45 | 43 | 45 | 40 | 27 | 39 | 33 | 35 | 30 | 42 | 35 | 29 | 32 | 28 | 26 |
| Exceptional Items | 0 | 0 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | -15 | 0 | 0 | 0 | -4 | 0 | 0 |
| EPS (Rs) | 3.3 | 3.8 | 3.8 | 3.9 | 3.6 | 2.4 | 3.4 | 2.9 | 3.0 | 2.5 | 3.7 | 3.1 | 2.6 | 2.9 | 2.6 | 2.3 |
| Sales Growth (YoY) | 2.1% | 21.6% | 1.8% | 26.7% | 20.0% | 5.7% | 5.0% | -7.6% | 5.4% | 13.7% | 13.4% | 13.7% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -6.4% | 18.0% | -7.0% | -0.5% | 11.4% | -1.2% | 15.8% | -5.8% | -1.9% | -1.9% | 1.9% | 7.5% | 5.8% | -2.1% | 2.2% | -- |
| OP Growth (YoY) | -8.9% | 37.0% | -10.9% | 42.9% | 9.8% | -16.4% | 1.9% | -17.6% | 15.9% | 25.0% | 28.6% | 27.5% | -- | -- | -- | -- |
| OP Growth (QoQ) | -19.0% | 28.6% | -18.3% | 7.1% | 21.7% | -16.4% | 31.0% | -17.6% | -7.3% | 1.9% | 5.9% | 15.9% | 0.0% | 4.8% | 5.0% | -- |
| Profit Growth (YoY) | -- | 62.0% | -9.0% | 32.0% | 17.0% | -30.0% | -10.0% | -5.0% | 19.0% | 8.0% | 42.0% | 31.0% | 61.0% | 43.0% | 7.1% | -11.8% |
| EPS Growth (YoY) | -7.3% | 62.0% | 12.8% | 31.6% | 17.1% | -6.3% | -9.9% | -4.5% | 18.2% | -11.8% | 42.2% | 31.6% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -13.8% | 1.1% | -1.8% | 8.4% | 50.6% | -29.7% | 14.6% | -3.6% | 20.6% | -32.4% | 21.4% | 19.4% | -10.1% | 9.1% | 12.4% | -- |
| OP Margin | 26.8% | 31.0% | 28.5% | 32.4% | 30.1% | 27.5% | 32.5% | 28.8% | 32.9% | 34.8% | 33.5% | 32.3% | 29.9% | 31.6% | 29.6% | 28.8% |
| Net Margin | 20.5% | 22.2% | 25.0% | 24.3% | 21.5% | 16.2% | 23.1% | 22.6% | 22.6% | 19.0% | 26.1% | 22.1% | 19.7% | 23.0% | 19.7% | 18.7% |
| Material Cost % | 26.2% | 28.0% | 24.1% | 24.1% | 26.9% | 27.6% | 23.0% | 22.4% | 22.2% | 22.5% | 21.8% | 23.4% | 25.1% | 24.2% | 26.4% | 24.2% |
| Employee Cost % | 23.5% | 20.6% | 24.0% | 21.3% | 21.4% | 22.0% | 20.4% | 24.3% | 22.4% | 20.9% | 19.9% | 20.1% | 21.3% | 21.6% | 20.4% | 20.0% |
| P/S | 4.48 | 4.87 | 5.63 | 4.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 20.24 | 21.51 | 26.25 | 22.78 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.06 | 2.23 | 2.69 | 2.26 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Transcript of Conference Call held on August 12, 2026 for the Unaudited Financial Results for the Quarter ended June 30, 2026
Please find enclosed herewith audio recording of earnings call held on August 12, 2026.
Bord Resolution for the Buyback
Public Announcement - BuyBack of the Equity Shares
Please find enclosed herewith the copy of newspaper publication of extract of unaudited consolidated financial results for the quarter ended June 30, 2026.
Un-audited Financial Results for the Quarter ended June 30, 2026
1) Approved acquistion of the remaining stake of 4.28% Equity Shares from the other existing Equity Shareholders of JC Biotech Private Limited (Exisitng Subsidiary) and 2) Approved infusion ....
Approved the Buy-Back of fully paid-up of Equity Shares of the Company via Open Market through Stock Exchanges
Earnings Presentation for the Quarter ended June 30, 2026
Press Release titled Quaterly Earnings Release dated August 08, 2026
1) Approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026 2)Approved the Buyback of fully paid-up equity shares 3)Approved ....
Scrutinizer Report and Voting Results - 37th Annual General Meeting
Proceeding of 37th Annual General Meeting (AGM) held on July 31, 2026
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 - for the Quarter ended June 30, 2026
Please find enclosed herewith copies of newspaper publication post completion of dispatch of Notice of 37th Annual general Meeting and Integrated Annual Report for FY 2025-2026.
Notice convening 37th Annual General Meeting of the Company scheduled to be held on Friday, July 31, 2026 at 10.00 a.m. (IST) through Video Conference or Other Audio Visual Means
Integrated Annual Report for FY 2025-2026
Copy of letter to Shareholders - Pursuant to Regulation 36(1)(b) of SEBI (LODR) Regulations, 2015
Business Responsibility and Sustainability Report for the financial year 2025-2026
Please find enclosed herewith copy of newspaper advertisement informing the shareholders about the 37th Annual General Meeting of the Company.
Please find enclosed herewith the intimation regarding the date of the 37th Annual general Meeting.
Please find enclosed herewith the intimation of record date for payment of final dividend.
Please find enclosed herewith the intimation regarding closure of trading window with effect from July 01, 2026.
Newspaper Publication - Notice to Equity Shareholders of the Company regarding transfer of shares to the Investor Education and Protection Fund (IEPF) and Unclaimed Dividend thereto / Second ....
Please find enclosed herewith intimation regarding completion of second term of Ms. Rajshree Patel as Independent Director of the Company.
Please find enclosed herewith the update regarding the additional investment in wholly owned subsidiary of the Company - Advanced Nutrazyme Private Limited.
Please find enclosed herewith the Annual Secretarial Compliance Report for year ended March 31, 2026.
Please find enclosed herewith the transcript of the earnings call held on May 12, 2026.
Please find enclosed herewith audio recording of earnings call held on May 12, 2026.
Please find enclosed herewith copy of newspaper publication of extract of audited consolidated financial results for quarter and year ended March 31, 2026.
Outcome of Board Meeting held on May 09, 2026
Re-appintment of M S K A & Associates LLP, Chartered Accountants as the Statutory Auditors of the Company for a second term of five consecutive years from the conclusion of the 37th Annual ....
Audited Financials Results (Standalone and Consolidated) for the quarter and financial year ended March 31, 2026
Recommended a Final Dividend - 67.5% i.e. Rs. 1.35/- per Equity Share on the face value of Rs. 2 each for the Financial Year 2025-26, Subject to the approval of the Shareholders at the ....
The Board Members in meeting held today has decided to defer the declaration of an Interim Dividend. While the Company continues to maintain health financial position and robust liquidity, ....
Re-appointment of Mr. Mukund Madhusudan Kabra (DIN: 00148294) as Whole Time Director of the Company for another term of 5 years effective from April 01, 2027, subject to the approval of ....
Quarterly Earnings Release dated May 09, 2026
Allotment of 49,350 Equity Shares of face value of Rs. 2/- per share pursuant to the Exercise of Options under Advanced Enzyme Technologies Limited - Employees Stock Options Scheme 2022.
Earnings Presentation for the Quarter and Year ended March 31, 2026
In terms of Regulation 30 and Schedule III to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has received the ....
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Company will ....
Advanced Enzyme Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2026 ,inter alia, to consider and approve Annual Financial ....
Please find enclosed herewith the above captioned certificate for quarter ended March 31, 2026.
In Continuation to our Intimation dated March 11, 2026 and in accordance with sub-para 7C of Para A of Part A of Schedule III of SEBI Listing Regulations- Resignation of Senior Management ....
Please find enclosed herewith the intimation of the closure of Trading Window with effect from April 01, 2026.
Resignation of Senior Mangement Personnel of the Company
In terms of Regulation 30 and Schedule III to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has received ....
Please find enclosed herewith news paper publication regarding special window for transfer and dematerialization of physical shares.
Please find enclosed herewith transcript of the earnings call held on February 04, 2026.
Please find enclosed herewith audio recording of earnings call held on February 04, 2026.
Annual Reports
16Credit Ratings
6Concalls
55Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Sep 2025
30 Sept 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022May 2022
31 May 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Nov 2021
30 Nov 2021Oct 2021
31 Oct 2021Sep 2021
30 Sept 2021Aug 2021
31 Aug 2021Jun 2021
30 Jun 2021Mar 2021
31 Mar 2021Feb 2021
28 Feb 2021Dec 2020
31 Dec 2020Nov 2020
30 Nov 2020Aug 2020
31 Aug 2020Aug 2020
31 Aug 2020Jun 2020
30 Jun 2020Mar 2020
31 Mar 2020Feb 2020
29 Feb 2020Feb 2020
29 Feb 2020Nov 2019
30 Nov 2019Nov 2019
30 Nov 2019Nov 2019
30 Nov 2019Aug 2019
31 Aug 2019May 2019
31 May 2019Nov 2018
30 Nov 2018Aug 2018
31 Aug 2018Jun 2018
30 Jun 2018May 2018
31 May 2018May 2018
31 May 2018May 2018
31 May 2018Feb 2018
28 Feb 2018Nov 2017
30 Nov 2017Sep 2017
30 Sept 2017Jun 2017
30 Jun 2017Jun 2017
30 Jun 2017May 2017
31 May 2017Mar 2017
31 Mar 2017Feb 2017
28 Feb 2017Nov 2016
30 Nov 2016Nov 2016
30 Nov 2016Held by ETFs
2 ETFs hold ADVENZYMES · sorted by weight
Held by Mutual Funds
6 schemes hold ADVENZYMES · sorted by weight